- Home
- IBRX vs JEF Comparison
IBRX vs JEF Comparison
Compare IBRX & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | JEF |
|---|---|---|
| Founded | 2014 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.5B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IBRX | JEF |
|---|---|---|
| Price | $7.94 | $52.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $12.57 | ★ $61.40 |
| AVG Volume (30 Days) | ★ 10.9M | 1.9M |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | $113,288,000.00 | ★ $10,823,677,000.00 |
| Revenue This Year | $88.59 | $13.23 |
| Revenue Next Year | $131.15 | $10.25 |
| P/E Ratio | ★ N/A | $74.69 |
| Revenue Growth | ★ 668.31 | 2.93 |
| 52 Week Low | $1.95 | $35.53 |
| 52 Week High | $12.43 | $71.04 |
Technical Indicators
Market Signals| Indicator | IBRX | JEF |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 63.41 |
| Support Level | $7.77 | $51.68 |
| Resistance Level | $8.51 | $58.69 |
| Average True Range (ATR) | 0.53 | 1.52 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 62.50 | 70.92 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About JEF Jefferies Financial Group Inc.
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.